

REMARKS

Claims 1-18, 24 and 25 were pending in the instant application. Applicants have canceled Claims 1, 9, 12-18, 24 and 25 in the instant application and currently amended Claims 2-3 and 6-8. WHEREIN, Claims 2-8 and 10-11 remain to be examined. No new matter has been added. No additional claims fee is believed to be due. Applicants reserve the right to prosecute the originally filed claims in the future.

Applicants have provided a new declaration in compliance with 37 CFR 1.67(a) for co-inventor Mark E. Duggan.

Applicants have amended the specification to correct the recurrent spelling errors in most of the compounds named which include the fragment "benzimidazole". Applicants have also amended the specification to correct spelling errors to compound names which include the fragments "imidazole" and "piperidine".

Examiner has rejected Claims 12-17 and 25 under 35 USC 112, first paragraph, based on enablement. While the Applicants disagree with the Examiner's assertion, in order to expedite prosecution, Applicants have canceled Claims 12-17 and 25.

Examiner has rejected Claims 12-14 under 35 USC 112, second paragraph, as being indefinite. While the Applicants disagree with the Examiner's assertion, in order to expedite prosecution, Applicants have canceled Claims 12-14.

Examiner has rejected Claims 1, 9 and 12 under 35 USC 102(b) as being anticipated by either Indian Journal of Chemistry, vol. 30B, pages 777-783 (1991) or IN 166761, both Venugapalan et al. Applicants have canceled Claims 1, 9 and 12.

Examiner has objected to Claims 6-8 because of recurrent spelling errors to "benzimidazole", "piperidin" and "imidazole". Applicants have corrected these spelling errors.

Examiner has objected to Claim 18 under 37 CFR 1.75 as being a substantial duplicate of Claim 9. Applicants have canceled Claim 18.

Applicants respectfully contend that the Examiner's rejections and objections are now moot, and that Claims 2-8 and 10-11 are allowable, and an early Notice of Allowance is earnestly solicited. If a telephonic communication with Applicant's representative will aid in the advancement of the prosecution of this application, please telephone the representative indicated below.

Respectfully submitted,

By: 

Matthew A. Leff
Registration No. 50,149
Attorney for Applicants

MERCK & CO., INC.
P.O. Box 2000 - RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-1404

Date: January 25, 2007